FogPharma, an oncology startup, has successfully closed a $145 million Series E financing round, a milestone that underscores its growth and potential in the biotech industry. The round, confirmed by the company, marks a significant phase of financing that is rarely achieved by biotech firms. Adding to its board, FogPharma has welcomed Alexis Borisy, a move that further solidifies its leadership as it continues to support cancer drug research. The financing was strongly backed by multiple blue-chip life sciences investors, highlighting the confidence in FogPharma's approach to cancer treatment. CEO Mathai Mammen expressed optimism about the company's mission, emphasizing the importance of making significant strides in a short life span with the statement, "Life is short. Let's try,…"